Gong Z, Xue L, Vlantis A, van Hasselt C, Chan J, Fang J, et al. Brusatol attenuated proliferation and invasion induced by KRAS in differentiated thyroid cancer through inhibiting Nrf2. J Endocrinol Invest. 2023;: pubmed publisher

Shin D, Jo J, Choi M, Kim K, Bae Y, Kim S. Oncogenic KRAS mutation confers chemoresistance by upregulating SIRT1 in non-small cell lung cancer. Exp Mol Med. 2023;55:2220-2237 pubmed publisher

Entrialgo Cadierno R, Cueto Ure xf1 a C, Welch C, Feliu I, Macaya I, Vera L, et al. The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer. Mol Cancer. 2023;22:86 pubmed publisher

Ricciuti B, Son J, Okoro J, Mira A, Patrucco E, Eum Y, et al. Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res. 2022;28:1640-1650 pubmed publisher

Sad K, Parashar P, Tripathi P, Hungyo H, Sistla R, Soni R, et al. Prochlorperazine enhances radiosensitivity of non-small cell lung carcinoma by stabilizing GDP-bound mutant KRAS conformation. Free Radic Biol Med. 2021;177:299-312 pubmed publisher

Mysore V, Zhou Z, Ambrogio C, Li L, Kapp J, Lu C, et al. A structural model of a Ras-Raf signalosome. Nat Struct Mol Biol. 2021;28:847-857 pubmed publisher

Li R, Ng T, Wang S, Prytyskach M, Rodell C, Mikula H, et al. Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer. Nat Nanotechnol. 2021;16:830-839 pubmed publisher

Zhou Z, Ambrogio C, Bera A, Li Q, Li X, Li L, et al. KRASQ61H preferentially signals through MAPK in a RAF dimer-dependent manner in non-small cell lung cancer. Cancer Res. 2020;: pubmed publisher

Inoue S, Hirota Y, Ueno T, Fukui Y, Yoshida E, Hayashi T, et al. Uterine adenomyosis is an oligoclonal disorder associated with KRAS mutations. Nat Commun. 2019;10:5785 pubmed publisher

Kalvala A, Wallet P, Yang L, Wang C, Li H, Nam A, et al. Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. J Clin Med. 2019;8: pubmed publisher

Li S, Liu S, Deng J, Akbay E, Hai J, Ambrogio C, et al. Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. Clin Cancer Res. 2018;24:4854-4864 pubmed publisher

Ambrogio C, Köhler J, Zhou Z, Wang H, Paranal R, Li J, et al. KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS. Cell. 2018;172:857-868.e15 pubmed publisher

Zeng M, Lu J, Li L, Feru F, Quan C, Gero T, et al. Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C. Cell Chem Biol. 2017;24:1005-1016.e3 pubmed publisher

Mulcahy Levy J, Zahedi S, Griesinger A, Morin A, Davies K, Aisner D, et al. Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. elife. 2017;6: pubmed publisher